Please login to the form below

Not currently logged in
Email:
Password:

eczema

This page shows the latest eczema news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... on the widely used Eczema Area and Severity Index (EASI) scale,

Latest news

More from news
Approximately 7 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Meanwhile, phase 2b results for upadacitinib showed that the drug was able to improve skin lesions and itching in patients with moderate-to- severe atopic dermatitis (eczema) across all doses tested,

  • Case Study: Skin-telligence Case Study: Skin-telligence

    One in two eczema sufferers aren’t happy with their treatment regime and actively switch products, trying different treatments to find the right one. ... Eczema has a psychological impact. Half of respondents said their skin affects their confidence.

  • Embracing digital disruption in pharma Embracing digital disruption in pharma

    HelloSkin is the number one online store for emollients, nutrition supplements, accessories and selected over-the-counter products for people living with psoriasis, eczema, acne and dry skin.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... Corporate acquisition. Acquisition for $99.25 per share [55%

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics